NaviMed Capital

What NaviMed Capital does

NaviMed Capital is a Washington, DC-based private investment firm focused exclusively on the healthcare industry. The firm partners with management teams of lower middle-market healthcare businesses, providing control and substantial minority equity investments typically ranging from $5 to $30 million per transaction. NaviMed targets profitable private companies with $10 to $100 million in revenue, up to $10 million in EBITDA, and double-digit revenue growth across healthcare services, healthcare IT, hospital products, and distribution sectors. The firm manages over $900 million in assets under management across Fund II ($290M, April 2021) and Fund III ($450M hard cap, November 2024), and has created over $6.5 billion in enterprise value since 1997 through its principals' prior and current investing activities.

NaviMed's core value proposition combines capital with operational enhancement, deep healthcare expertise, and an extensive network of relationships with industry leaders and health policy-makers. The firm's revenue model is based on traditional private equity economics: management fees on committed capital across its fund vehicles, plus carried interest from successful portfolio exits. The current portfolio spans 14 companies across diverse healthcare verticals including behavioral health (BrentCare, CenterPointe), wound care (Advantage Surgical), clinical research (Velocity Clinical, exited to GHO Capital), revenue cycle management (Argos Health/EnableComp, exited to Welsh Carson), medical device services (ClariMed), pharmacy (Vitoria), rehabilitation (Neulife), oncology management services (OPN Healthcare), and lab services (Lighthouse Lab Services). Notable exits include CenterPointe (acquired by Acadia Healthcare), Lucent Health (acquired by Gauge Capital in 2024), The CM Group (acquired by OPEN Health), and Velocity Clinical Research (acquired by GHO Capital).

The firm is led by Managing Directors Ryan Schwarz, Bijan Salehizadeh M.D., Brian Canann, and Ryan Ross, supported by Executive Partners Art Glasgow (joined July 2025, healthcare supply chain focus) and Beth Landry (joined April 2026, home health/post-acute care focus), plus a team of 20+ investment and operations professionals. Team members bring backgrounds from The Carlyle Group, Highland Capital Partners, Cerner/Oracle Health, Optum, Lumeris, Duke Medicine, the U.S. Senate, and top-tier investment banks. NaviMed's go-to-market relies on proprietary deal flow through deep healthcare relationships rather than competitive auction processes, with limited geographic focus on North America.

Name

NaviMed Capital

Legal name

NaviMed Capital Advisors, LLC

Website

https://navimed.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

NaviMed Capital is a Washington, DC-based private equity firm exclusively focused on healthcare. It makes control and minority equity investments of $5-$30 million in lower middle-market healthcare businesses with up to $10 million in EBITDA, managing over $900 million in AUM across three funds.

Ownership category

akta.pro rank

Product category

Private Equity Healthcare Investment

NAICS

All Other Financial Investment Activities (52399), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523), Miscellaneous Financial Investment Activities (523999)

SIC

Investment Advice (6282), Investors, Nec (6799), Services-Management Consulting Services (8742)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Healthcare private equity
• Growth buyout investments
• Lower middle market
• Healthcare investment firm
• Portfolio management services

Headquarters

HQ city

Arlington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Management Fees: Private equity firm generates revenue through management fees charged on assets under management across its fund vehicles (Fund I, Fund II, Fund III).
2. Carried Interest: Performance-based carried interest from successful portfolio company exits and realizations across its investment funds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NaviMed Capital is a Washington, DC-based private investment firm that makes control and substantial minority equity investments in lower middle-market healthcare businesses. The firm partners with management teams by providing capital to support organic and inorganic growth, facilitating founder liquidity, and offering strategic expertise, typically deploying equity investments of $5 to $30 million per transaction in companies with $10 to $100 million of revenue and up to $10 million of EBITDA.

Product overview

NaviMed Capital is a healthcare-focused private equity investment firm, not a software product company. The firm's core offering is its private equity investment platform, which provides capital to support both organic and inorganic growth of healthcare businesses. NaviMed targets control and substantial minority investments in North American healthcare services, healthcare IT, hospital products, and distribution businesses. Their investment criteria focus on companies with $10 to $100 million of revenue and up to $10 million of EBITDA. The firm's portfolio consists of 14 current and partially exited portfolio companies across healthcare services including specialty services (wound care, behavioral health), payors/payments, providers, outsourced pharma services, clinical research, rehabilitation, pharmacy services, management services, and marketing services. Notable portfolio companies include Advantage Surgical, BrentCare, Citrus Health, ClariMed, Infusive, Lighthouse Lab Services, Neulife, OPN Healthcare, Prime Therapy, TILT, and Vitoria. Previously exited investments include CenterPointe Behavioral Health System (acquired by Acadia Healthcare), The CM Group (acquired by OPEN Health), Lucent Health (acquired by Gauge Capital), and Velocity Clinical Research (acquired by GHO Capital).

Differentiator

Problem solved

Functional benefit

Products and services

• NaviMed Capital Investment Platform

Quantifiable outcome

• Over $6.5 billion of enterprise value created since 1997
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Welsh, Carson, Anderson & Stowe: Healthcare-specialist PE firm that acquired NaviMed's Argos Health (now EnableComp) in 2021. Targets control healthcare growth investments at similar scale to NaviMed, making it the most directly comparable competitor.
• Linden Capital Partners: Healthcare-focused middle-market PE firm investing in healthcare services, products, and distribution — directly overlapping NaviMed's services and distribution thesis with similar deal sizes.
• Frazier Healthcare Partners: Long-established healthcare-dedicated PE firm with growth and buyout funds targeting profitable lower-middle-market healthcare businesses — closely comparable mandate and stage to NaviMed.
• Webster Equity Partners: Healthcare-services-focused PE firm investing in lower-middle-market providers and outsourced services — strong comparable on healthcare services buy-and-build thesis.
• Varsity Healthcare Partners: Lower-middle-market healthcare services PE firm with focus on founder-led businesses and provider/payor services — directly overlaps NaviMed's core target market.
• Martis Capital: Healthcare-focused growth equity firm that partnered with NaviMed on Lighthouse Lab Services recapitalization in 2021 — directly comparable healthcare growth mandate.
• Avista Capital Partners: Healthcare-focused PE firm that has invested in healthcare services, products, and distribution businesses — comparable sector focus and lower-middle-market orientation.
• DW Healthcare Partners: Lower-middle-market healthcare PE firm investing in branded products, generics, and healthcare IT — prior employer of NaviMed Principal Josh Boylan; directly comparable mandate.
• Gauge Capital: Lower-middle-market PE firm with significant healthcare exposure; acquired NaviMed portfolio company Lucent Health in 2024 — directly comparable in healthcare services investing.

Broad incumbents

• TPG Capital: Mega-cap PE platform with a dedicated healthcare team investing across services, products, and technology at scale; overlaps with NaviMed's healthcare services thesis but at much larger deal sizes and broader scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/navimed-capital
• Xx.com/NaviMed

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NaviMed Capital